EUVIMEDEUVIMED entdecken
Crossref

The Therapeutic Potential of Complement Inhibitors in Xenoreactive Human Complement‐Dependent Cytotoxicity in Vitro

Krish Vasudev iD, Maho Terashita iD, David K C Cooper iD, Akihiro Maenaka iD

Xenotransplantation · 2026-05 · 33 (3)

DOI: 10.1111/xen.70146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Xenotransplantation, online erschienen am 02.06.2026. Verfasst von Krish Vasudev und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Complement Inactivating Agents, Complement Activation, Transplantation, Heterologous, Complement System Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: American Society of Nephrology, U.S. Department of Health and Human Services, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Complement activation is critical in xenograft rejection, but the relative efficacy of pharmacological complement inhibitors remains unclear.

Methods

Peripheral blood mononuclear cells (PBMCs) from wild‐type (WT) pigs were exposed to human serum in the presence or absence of complement inhibitors. Complement‐dependent cytotoxicity (CDC) and complement deposition were measured by flow cytometry. A C1s inhibitor (sutimlimab, 12.5–800 µg/mL), a C1‐esterase inhibitor (berinert, 1.25–10U/mL), a C3/C3b inhibitor (pegcetacoplan, 0.25–4.0 mg/mL), and a C5 inhibitor (tesidolumab, 500–800 µg/mL) were applied to dose‐response assays.

Results

Only pegcetacoplan (C3/C3b inhibitor) achieved complete inhibition of CDC with minimal C3b/iC3b and C5b‐9 deposition. Sutimlimab (C1s inhibitor) produced partial inhibition of CDC (hitting a plateau) and complement deposition, while C1‐esterase inhibitor had limited CDC effect and did not reduce C3b/iC3b. Tesidolumab (C5 inhibitor) suppressed C5b‐9 but failed to prevent CDC or upstream opsonization.

Conclusions

Although these results might reflect experiments conducted at concentrations lower than clinical doses, our data suggest that, of the limited number of agents tested, pegcetacoplan may be the most effective in inhibiting xenoreactive human complement activation in this experimental setting (i.e., CDC of human complement in the pooled‐serum against WT pig PBMCs). However, the results we obtained are puzzling because the C5 inhibitor, eculizumab, has been proven to be highly effective in inhibiting human complement activation in the in vitro CDC model. Furthermore, tesidolumab was reported to be effective in an in vivo NHP model. To obtain the additional information required for clinical application, further investigation would be needed. We would need to (i) ensure that the tesidolumab we were using had not deteriorated in any way and lost its efficacy, and (ii) compared pegcetacoplan with other C5 inhibitors (e.g., ravulizumab, eculizumab).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Complement Inactivating AgentsComplement ActivationTransplantation, HeterologousComplement System ProteinsCytotoxicity, ImmunologicGraft RejectionAnimalsHumansSwineLeukocytes, Mononuclear

Stichwörter der Autor:innen

complementcomplement inhibitorspigxenotransplantation

Substanzen

Complement Inactivating AgentsComplement System Proteins

Autor:innen und Institutionen

  • Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Krish Vasudev, Maho Terashita, David K C Cooper, Akihiro Maenaka

Förderung

  • American Society of Nephrology
  • U.S. Department of Health and Human Services
  • National Institutes of Health

Zitieren

APA

Vasudev, K., Terashita, M., Cooper, D. K. C., & Maenaka, A. (2026). The Therapeutic Potential of Complement Inhibitors in Xenoreactive Human Complement‐Dependent Cytotoxicity in Vitro. Xenotransplantation, 33(3). https://doi.org/10.1111/xen.70146

Vancouver

Vasudev K, Terashita M, Cooper DKC, Maenaka A. The Therapeutic Potential of Complement Inhibitors in Xenoreactive Human Complement‐Dependent Cytotoxicity in Vitro. Xenotransplantation. 2026;33(3). doi:10.1111/xen.70146

BibTeX
@article{Vasudev2026,
  author = {Vasudev, Krish and Terashita, Maho and Cooper, David K C and Maenaka, Akihiro},
  title = {The Therapeutic Potential of Complement Inhibitors in Xenoreactive Human Complement‐Dependent Cytotoxicity in Vitro},
  journal = {Xenotransplantation},
  year = {2026},
  volume = {33},
  number = {3},
  doi = {10.1111/xen.70146}
}
Kostenlos starten →